A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF‐β signals
暂无分享,去创建一个
K. Miyazono | M. Kawabata | K. Yagi | I. Iwamoto | Mitsuyasu Kato | D. Goto | M. Kato | H. Inoue | Daisuke Goto | Ken Yagi | Hirofumi Inoue | Itsuo Iwamoto | Itsuo Iwamoto
[1] Yigong Shi,et al. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF‐β receptors , 1998, The EMBO journal.
[2] Y. Yuasa,et al. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. , 1998, Cancer letters.
[3] Kohei Miyazono,et al. TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.
[4] Xiao-Fan Wang,et al. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein , 1997, Molecular and cellular biology.
[5] J. Massagué,et al. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. , 1997, Genes & development.
[6] C. Wernstedt,et al. Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-β Signaling* , 1997, The Journal of Biological Chemistry.
[7] Jeffrey L. Wrana,et al. TβRI Phosphorylation of Smad2 on Ser465 and Ser467 Is Required for Smad2-Smad4 Complex Formation and Signaling* , 1997, The Journal of Biological Chemistry.
[8] C. Heldin,et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.
[9] K. Miyazono,et al. Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.
[10] R. Weinberg,et al. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] Takeshi Imamura,et al. TGF‐β receptor‐mediated signalling through Smad2, Smad3 and Smad4 , 1997 .
[12] Yigong Shi,et al. A structural basis for mutational inactivation of the tumour suppressor Smad4 , 1997, Nature.
[13] K. Kinzler,et al. Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.
[14] J. Wrana,et al. The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.
[15] A. Roberts,et al. Characterization of Functional Domains within Smad4/DPC4* , 1997, The Journal of Biological Chemistry.
[16] A. Hata,et al. TGF-β signalling through the Smad pathway , 1997 .
[17] R. Derynck,et al. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4 , 1997, Molecular and cellular biology.
[18] P. Dijke,et al. DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells , 1997, Oncogene.
[19] C. Heldin,et al. Identification of Smad2, a Human Mad-related Protein in the Transforming Growth Factor β Signaling Pathway* , 1997, The Journal of Biological Chemistry.
[20] P. Hoodless,et al. MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling , 1996, Cell.
[21] Y. Takagi,et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. , 1996, Gastroenterology.
[22] J. Massagué,et al. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.
[23] R. Derynck,et al. Receptor-associated Mad homologues synergize as effectors of the TGF-β response , 1996, Nature.
[24] Irene L Andrulis,et al. MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.
[25] Scott E. Kern,et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.
[26] T. Mitsudomi,et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.
[27] Anita B. Roberts,et al. Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .
[28] Kathleen R. Cho,et al. DPC4 gene in various tumor types. , 1996, Cancer research.
[29] R. Lotan,et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. , 1996, Cancer research.
[30] Scott E. Kern,et al. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.
[31] Luzhe Sun,et al. Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells (*) , 1995, The Journal of Biological Chemistry.
[32] K. Kinzler,et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.
[33] K. Miyazono,et al. A Human Keratinocyte Cell Line Produces Two Autocrine Growth Inhibitors, Transforming Growth Factor-β and Insulin-like Growth Factor Binding Protein-6, in a Calcium- and Cell Density-dependent Manner (*) , 1995, The Journal of Biological Chemistry.
[34] M. Sporn,et al. Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β) , 1993 .